Firefly Neuroscience Q2 FY26 net loss widens 8.24% to $US 1.98 million; revenue rises 72% to $US 514,000 - AIFF News | RalliesFirefly Neuroscience Q2 FY26 net loss widens 8.24% to $US 1.98 million; revenue rises 72% to $US 514,000
A
AIFF• Cash position and operating update
- Cash totaled $9.23 million at June 30, 2026, up from $2.75 million at year-end 2025 after $10.25 million in gross private-placement proceeds.
- The Evoke EEG System was in use across more than 85 U.S. clinical sites as of June 30, 2026; no shares were sold under its $7.43 million ATM program.
Q2 revenue rises as net loss widens
- Firefly Neuroscience posted a Q2 net loss of $1.98 million, widening from the prior-year quarter’s $1.83 million loss.
- Revenue rose 72% year over year to $514,000, reflecting contributions from the Evoke Neuroscience acquisition.
- Operating loss widened to $1.97 million, while research and development expense increased 56% to $525,000 on higher product-development spending.
NVRI
•
